Alnylam Pharmaceuticals (ALNY) Short Interest Ratio & Short Volume → Have You Seen Elon’s New A.I. Device? (Picture Inside) (From InvestorPlace) (Ad) Free ALNY Stock Alerts $150.31 +0.35 (+0.23%) (As of 05/2/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Alnylam Pharmaceuticals Short Interest DataCurrent Short Volume2,500,000 sharesPrevious Short Volume2,800,000 sharesChange Vs. Previous Month-10.71%Dollar Volume Sold Short$369.25 millionShort Interest Ratio / Days to Cover3.0Last Record DateApril 15, 2024Outstanding Shares125,950,000 sharesPercentage of Shares Shorted1.98%Today's Trading Volume660,073 sharesAverage Trading Volume767,151 sharesToday's Volume Vs. Average86% Short Selling Alnylam Pharmaceuticals ? Sign up to receive the latest short interest report for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort InterestDays to CoverShort Percent of FloatALNY Short Interest Over TimeALNY Days to Cover Over TimeALNY Percentage of Float Shorted Over Time Ad Stansberry ResearchThe Long-Awaited End of America UpdateA 995% Gain Last Time We Shared this "Election Secret" It's a straightforward way to come out on top no matter who wins this November… It's not cryptos, or options, and anyone can do it.Click here to find out for free. Alnylam Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 4/15/20242,500,000 shares $369.25 million -10.7%N/A3 $147.70 3/31/20242,800,000 shares $418.46 million +4.1%N/A3.3 $149.45 3/15/20242,690,000 shares $401.54 million -11.5%N/A3.2 $149.27 2/29/20243,040,000 shares $459.31 million -23.8%N/A3.6 $151.09 2/15/20243,990,000 shares $588.25 million -0.5%N/A5 $147.43 1/31/20244,010,000 shares $693.37 million -7.4%N/A6.5 $172.91 Get the Latest News and Ratings for ALNY and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Alnylam Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 1/15/20244,330,000 shares $837.38 million -8.5%N/A7.4 $193.39 12/31/20234,730,000 shares $905.37 million -5.2%N/A7.6 $191.41 12/15/20234,990,000 shares $924.35 million -2.0%N/A7.8 $185.24 11/30/20235,090,000 shares $856.39 million -1.9%N/A7.6 $168.25 11/15/20235,190,000 shares $887.75 million -1.5%N/A8 $171.05 10/31/20235,270,000 shares $799.99 million -1.7%N/A8.3 $151.80 10/15/20235,360,000 shares $901.12 million +3.9%N/A8.7 $168.12 9/30/20235,160,000 shares $913.84 million +0.2%N/A8.6 $177.10 9/15/20235,150,000 shares $952.70 million -2.8%N/A9 $184.99 8/31/20235,300,000 shares $1.05 billion -1.5%N/A9.9 $197.82 8/15/20235,380,000 shares $969.10 million +1.7%N/A10.2 $180.13 7/31/20235,290,000 shares $1.03 billion +6.9%N/A9.7 $195.40 7/15/20234,950,000 shares $975.65 million -0.6%N/A8.4 $197.10 6/30/20234,980,000 shares $945.90 million +0.4%N/A8 $189.94 6/15/20234,960,000 shares $1.00 billion -1.8%N/A7.4 $202.34 5/31/20235,050,000 shares $934.30 million -1.4%N/A7 $185.01 5/15/20235,120,000 shares $1.06 billion +0.8%N/A6.3 $206.20 4/30/20235,080,000 shares $1.01 billion +2.2%N/A6.2 $199.20 4/15/20234,970,000 shares $1.01 billion -4.1%N/A6 $203.92 3/31/20235,180,000 shares $1.04 billion +5.1%N/A6.4 $200.32 3/15/20234,930,000 shares $915.75 million -8.5%N/A6.3 $185.75 2/28/20235,390,000 shares $1.03 billion +5.7%N/A7 $191.45 2/15/20235,100,000 shares $1.13 billion -4.3%N/A6.5 $222.10 1/31/20235,330,000 shares $1.21 billion -6.2%N/A7.1 $226.40 1/15/20235,680,000 shares $1.34 billion +11.2%N/A7.3 $235.53 12/30/20225,110,000 shares $1.21 billion -5.4%N/A6.2 $237.65 12/15/20225,400,000 shares $1.24 billion +8.2%N/A6.1 $229.37 11/30/20224,990,000 shares $1.10 billion -10.3%N/A5.1 $220.59 11/15/20225,560,000 shares $1.19 billion -7.8%N/A5.7 $214.29 10/31/20226,030,000 shares $1.25 billion +25.6%N/A6.1 $207.26 10/15/20224,800,000 shares $890.54 million +5.7%N/A4.2 $185.53 9/30/20224,540,000 shares $908.73 million +3.7%N/A4.2 $200.16 9/15/20224,380,000 shares $913.14 million +4.3%N/A4.2 $208.48 8/31/20224,200,000 shares $868.01 million -16.0%N/A4 $206.67Urgent Nvidia Warning (Ad)Could Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… ALNY Short Interest - Frequently Asked Questions What is Alnylam Pharmaceuticals' current short interest? Short interest is the volume of Alnylam Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of April 15th, investors have sold 2,500,000 shares of ALNY short. Learn More on Alnylam Pharmaceuticals' current short interest. What is a good short interest ratio for Alnylam Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. ALNY shares currently have a short interest ratio of 3.0. Learn More on Alnylam Pharmaceuticals's short interest ratio. Which institutional investors are shorting Alnylam Pharmaceuticals? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Alnylam Pharmaceuticals: Concourse Financial Group Securities Inc., Simplex Trading LLC, Portman Square Capital LLP, UBS Group AG, BNP Paribas Financial Markets, Concourse Financial Group Securities Inc., and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Alnylam Pharmaceuticals' short interest increasing or decreasing? Alnylam Pharmaceuticals saw a decrease in short interest in April. As of April 15th, there was short interest totaling 2,500,000 shares, a decrease of 10.7% from the previous total of 2,800,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Alnylam Pharmaceuticals' short interest compare to its competitors? Here is how the short interest of companies compare to Alnylam Pharmaceuticals: Royalty Pharma plc (3.74%), BioMarin Pharmaceutical Inc. (1.94%), United Therapeutics Co. (9.96%), Ionis Pharmaceuticals, Inc. (7.12%), Genmab A/S (0.40%), Teva Pharmaceutical Industries Limited (1.04%), BeiGene, Ltd. (1.92%), Viatris Inc. (3.55%), Karuna Therapeutics, Inc. (5.16%), Dr. Reddy's Laboratories Limited (0.45%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.70 billion), Occidental Petroleum Co. ($3.52 billion), Charter Communications, Inc. ($3.14 billion), General Motors ($2.68 billion), Coinbase Global, Inc. ($2.57 billion), Moderna, Inc. ($2.18 billion), Tractor Supply ($2.10 billion), Royal Caribbean Cruises Ltd. ($1.91 billion), TC Energy Co. ($1.90 billion), and Williams-Sonoma, Inc. ($1.78 billion). View all of the most shorted stocks. What does it mean to sell short Alnylam Pharmaceuticals stock? Short selling ALNY is an investing strategy that aims to generate trading profit from Alnylam Pharmaceuticals as its price is falling. ALNY shares are trading up $0.35 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Alnylam Pharmaceuticals? A short squeeze for Alnylam Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ALNY, which in turn drives the price of the stock up even further. How often is Alnylam Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALNY, twice per month. The most recent reporting period available is April, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Royalty Pharma Short Interest BioMarin Pharmaceutical Short Interest United Therapeutics Short Interest Ionis Pharmaceuticals Short Interest Genmab A/S Short Interest Teva Pharmaceutical Industries Short Interest BeiGene Short Interest Viatris Short Interest Karuna Therapeutics Short Interest Dr. Reddy's Laboratories Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:ALNY) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersUrgent Nvidia WarningAltimetryA.I. is a Tidal Wave - Here’s What to BuyChaikin AnalyticsTruth about Trump you’ve never heardPorter & CompanyHe Is Giving Away BitcoinCrypto Swap ProfitsThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingThe A.I. story nobody is telling you (Read ASAP)TradeSmithAI “wealth window” is closing June 25thParadigm Press4 Cryptos BETTER than BitcoinTrue Market Insiders